NTC, an Italian pharmaceutical company specializing in ophthalmology, has developed the first eyedrops containing a fluoroquinolone wide spectrum antibiotic and a standard of care cortisone for the post-surgical treatment of cataract. The drug reduces the duration of therapy after surgery by 50%.

NTC, an international R&D focused pharmaceutical company headquartered in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agreement for exclusive license and distribution rights of NTC014, innovative fixed combination of a quinolone antibiotic and a NSAID in eye drops.

NTC Srl, R&D focused pharmaceutical company headquartered in Italy, has obtained CE certifications for three medical devices based on TIAB technology: a new vaginal gel GENIGEL, a proctological cream-gel TIAHEM and a powder for wound care TIAHEL.

NTC Srl, an R&D focused pharmaceutical company headquartered in Italy, has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries (”Taro”), a research-based international pharmaceutical company.